Autoimmune Thrombocytopenia in SLE and COVID-19

Yeremia Suryo Pratama, Riska Pradiptakirana, Azkia Rachmah, Nurhasan Agung Prabowo, Yeremia Suryo Pratama, Riska Pradiptakirana, Azkia Rachmah, Nurhasan Agung Prabowo

Abstract

Thrombocytopenia and hypercoagulopathy are haematological abnormalities commonly seen in individuals with coronavirus disease 2019 (COVID-19) and systemic lupus erythematosus (SLE). The difficulty arises when the patient has both diseases concurrently. The clinician should be able to comprehend the pathophysiology of these patient abnormalities in order to provide the best treatment possible. We present a case of a 20-year-old female COVID-19 patient with a history of SLE who had thrombocytopenia but normal D-dimer results. Our analysis revealed that the thrombocytopenia may have been caused by a relapse of lupus, not by COVID-19 infection. In this case, glucocorticoids were the primary therapy and produced excellent results.

Learning points: The pathophysiology of thrombocytopenia in a patient with concurrent COVID-19 and SLE should not always be associated with platelet consumption.Low-dose glucocorticoids should be administered, with infection risk and comorbidities taken into consideration.Glucocorticoid therapy may result in a delay in viral clearance.

Keywords: COVID-19; SLE; hypercoagulopathy; thrombocytopenia.

Conflict of interest statement

Conflicts of Interests: The authors declare there are no competing interests.

© EFIM 2021.

Figures

Figure 1
Figure 1
The chest x-ray showed multiple infiltrates in both lung fields depicting bronchopneumonia
Figure 2
Figure 2
Platelet counts of the patient from admission to the last day hospitalized. The platelet count continued to increase gradually. It reached the normal range on the third day of hospitalization and continued to increase until the patient was discharged

References

    1. Yang X, Yang Q, Wang Y, Wu Y, Xu J, Yu Y, et al. Thrombocytopenia and its association with mortality in patients with COVID-19. J Thromb Haemost. 2020;18(6):1469–1472.
    1. Xu P, Zhou Q, Xu J. Mechanism of thrombocytopenia in COVID-19 patients. Ann Hematol. 2020;99(6):1205–1208.
    1. Vidali S, Morosetti D, Cossu E, Luisi MLE, Pancani S, Semeraro V, et al. D-dimer as an indicator of prognosis in SARS-CoV-2 infection: a systematic review. ERJ Open Res. 2020;6(2):00260–2020.
    1. Rostami M, Mansouritorghabeh H. D-dimer level in COVID-19 infection: a systematic review. Expert Rev Hematol. 2020;13(11):1265–1275.
    1. Han H, Yang L, Liu R, Liu F, Liu F, Wu KL, et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med. 2020;58(7):1116–1120.
    1. Wu H, Birmingham DJ, Rovin B, Hackshaw KV, Haddad N, Haden D, et al. D-dimer level and the risk for thrombosis in systemic lupus erythematosus. Clin J Am Soc Nephrol. 2008;3(6):1628–1636.
    1. Sufian ABMA, Kashem M, Biswas S. Pattern of hematological manifestations in patients with systemic lupus erythematosus attending in a tertiary care hospita. J Med. 2017;18(2):86–91.
    1. Hayden A, Vyas-Lahar A, Rella V, Rudinskaya A. Severe refractory thrombocytopenia in a woman positive for coronavirus disease 2019 with lupus and antiphospholipid syndrome. Lupus. 2020;29(11):1472–1474.
    1. Bao C, Tao X, Cui W, Yi B, Pan T, Young K, et al. SARS-CoV-2 induced thrombocytopenia as an important biomarker significantly correlated with abnormal coagulation function, increased intravascular blood clot risk and mortality in COVID-19 patients. Exp Hematol Oncol. 2020;9:16.
    1. Zucchi D, Tani C, Elefante E, Stagnaro C, Carli L, Signorini V, et al. Impact of first wave of SARS-CoV-2 infection in patients with systemic lupus erythematosus: weighting the risk of infection and flare. PLoS One. 2021;16:e0245274.
    1. RECOVERY collaborative group et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693–704.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다